CDNA May 2024 5.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:13PM EDT. Market open.
| Previous close | 4.7000 |
| Open | N/A |
| Bid | 3.1000 |
| Ask | 7.5000 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 4.7000 - 4.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
Business WireLandmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
BRISBANE, Calif., May 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.
Simply Wall St.Earnings Update: Here's Why Analysts Just Lifted Their CareDx, Inc (NASDAQ:CDNA) Price Target To US$13.80
As you might know, CareDx, Inc ( NASDAQ:CDNA ) just kicked off its latest quarterly results with some very strong...
- GuruFocus.com
CareDx Reports Mixed Q1 2024 Results; Raises Annual Revenue Guidance
Despite a Quarterly Revenue Decline, CareDx Optimistic About 2024 Prospects
© 2024 Yahoo. All rights reserved.